Spirito L, Manfredi C, La Rocca R, Napolitano L, Di Girolamo A, Capece M, et al. Daily low-dose tadalafil may reduce the penile curvature progression rate in patients with acute Peyronie’s disease: a retrospective comparative analysis. Int J Impot Res. 2022. https://doi.org/10.1038/s41443-022-00651-8.

Article  PubMed  Google Scholar 

de la Peyronie F. Sur quelques obstacles qui s’ opposent a l’ejaculation naturelle de la semence. Mem Acad R Chir. 1743;1:425–34.

Google Scholar 

Mohede DCJ, de Jong IJ, van Driel MF. Medical treatments of peyronie’s disease: past, present, and future. Urology. 2019;125:1–5.

Article  PubMed  Google Scholar 

Tsambarlis P, Levine LA. Nonsurgical management of Peyronie’s disease. Nat Rev Urol. 2019;16:172–86.

Article  PubMed  Google Scholar 

Deng H, Li-Tsang CWP. Measurement of vascularity in the scar: a systematic review. Burns. 2019;45:1253–65.

Article  PubMed  Google Scholar 

Piraino J, Chaudhary H, Ames K, Okoye F 3rd, Sterling M, Clavell-Hernandez J, et al. A consistent lack of consistency in defining the acute and chronic phases of Peyronie’s disease: a review of the contemporary literature. Sex Med Rev. 2022;10:698–713.

Article  PubMed  Google Scholar 

Manka MG, White LA, Yafi FA, Mulhall JP, Levine LA, Ziegelmann MJ. Comparing and contrasting peyronie’s disease guidelines: points of consensus and deviation. J Sex Med. 2021;18:363–75.

Article  PubMed  PubMed Central  Google Scholar 

Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast cultures. Nitric Oxide. 2003;9:229–44.

Article  CAS  PubMed  Google Scholar 

Ilg MM, Stafford SJ, Mateus M, Bustin SA, Carpenter MJ, Muneer A, et al. Phosphodiesterase type 5 inhibitors and selective estrogen receptor modulators can prevent but not reverse myofibroblast transformation in Peyronie’s disease. J Sex Med. 2020;17:1848–64.

Article  CAS  PubMed  Google Scholar 

Ilg MM, Mateus M, Stebbeds WJ, Milenkovic U, Christopher N, Muneer A, et al. Antifibrotic synergy between phosphodiesterase type 5 inhibitors and selective oestrogen receptor modulators in Peyronie’s disease models. Eur Urol. 2019;75:329–40.

Article  CAS  PubMed  Google Scholar 

Chung E, Deyoung L, Brock GB. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J Sex Med. 2011;8:1472–7.

Article  CAS  PubMed  Google Scholar 

Lindsay MB, Schain DM, Grambsch P, Benson RC, Beard CM, Kurland LT. The incidence of Peyronie’s disease in Rochester, Minnesota, 1950 through 1984. J Urol. 1991;146:1007–9.

Article  CAS  PubMed  Google Scholar 

Burri A, Porst H. The relationship between penile deformity, age, psychological bother, and erectile dysfunction in a sample of men with Peyronie’s Disease (PD). Int J Impot Res. 2018;30:171–8.

Article  PubMed  Google Scholar 

Wang Y, Bao Y, Liu J, Duan L, Cui Y. Tadalafil 5 mg once daily improves lower urinary tract symptoms and erectile dysfunction: a systematic review and meta-analysis. Low Urin Trac Symptoms. 2018;10:84–92.

Article  Google Scholar 

Goberdhan S, Blachman-Braun R, Nackeeran S, Masterson TA 3rd, Ramasamy R. Is tadalafil associated with decreased risk of major adverse cardiac events or venous thromboembolism in men with lower urinary tract symptoms? World J Urol. 2022;40:1799–803.

Article  CAS  PubMed  PubMed Central  Google Scholar